



John P. Butler

Mr. Butler has served as President and CEO of Akebia Therapeutics since 2013. Akebia is based in Cambridge, Massachusetts and is a biomedical company dedicated to the research and development of innovative therapies for patients with kidney disease. Prior to Akebia, Mr. Butler was the CEO of Inspiration Biopharmaceuticals and has also held various positions at Genzyme Corporation, one of the world's largest biotechnology companies. At Genzyme, he led the company's renal, endocrinology, cardiovascular and rare disease businesses developing first-to-market and transformative therapies. Earlier in his career, he held sales and marketing positions at Amgen and Hoffman-La Roche. Mr. Butler received his BA degree in Chemistry from Manhattan University and his MBA degree from Baruch College.

Mr. Butler has spent over thirty years working to improve the lives of patients with kidney disease. He has been a longtime member of the American Kidney Fund Board of Trustees, including as Chair from 2013-2015. He is an active member of Kidney Care Partners, a unique coalition representing the broad kidney community, including serving as Chair from 2020-2024. He was a member of the Board of Directors of Relypsa and served as Chairperson of the Board at Keryx Biopharmaceuticals. Mr. Butler currently serves as a member of the Governing Board of the Biotechnology Innovation Organization (BIO).